These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26597302)

  • 41. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
    Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
    Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
    Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
    J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology.
    Frankel PH; Chung V; Xing Y; Longmate J; Groshen S; Newman EM
    Curr Probl Cancer; 2020 Dec; 44(6):100583. PubMed ID: 32446637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.
    Seymour L; Eisenhauer E
    Cancer Chemother Pharmacol; 2001; 47(1):2-10. PubMed ID: 11221956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
    de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
    Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
    Tosi D; Laghzali Y; Vinches M; Alexandre M; Homicsko K; Fasolo A; Del Conte G; Durigova A; Hayaoui N; Gourgou S; Gianni L; Mollevi C
    J Clin Oncol; 2015 Jul; 33(19):2158-65. PubMed ID: 26014300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamic biomarkers: falling short of the mark?
    Gainor JF; Longo DL; Chabner BA
    Clin Cancer Res; 2014 May; 20(10):2587-94. PubMed ID: 24831281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
    Ferte C; Soria JC; Penel N
    PLoS One; 2011 Mar; 6(3):e16633. PubMed ID: 21415927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.
    Jessen BA; Cornwell P; Redmond S; Visalli T; Lemper M; Bunch T; Hart T
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):455-464. PubMed ID: 37505272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
    Smart K; Bröske AM; Rüttinger D; Mueller C; Phipps A; Walz AC; Ries C; Baehner M; Cannarile M; Meneses-Lorente G
    Clin Pharmacol Ther; 2020 Sep; 108(3):616-624. PubMed ID: 32575160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The true face of the revolution in oncology drug development: a personal reflection.
    Burgess M; de Alwis DP
    Curr Clin Pharmacol; 2007 Jan; 2(1):31-5. PubMed ID: 18690853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.
    Ji Y; Huang PH; Woolfenden S; Myers A
    Clin Transl Sci; 2022 Jul; 15(7):1713-1722. PubMed ID: 35620969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Late phase 1 studies: concepts and outcomes.
    Benitez JC; Geraud A; Texier M; Massard C; Paci A; Soria JC; Besse B
    Lancet Oncol; 2021 Oct; 22(10):e446-e455. PubMed ID: 34592194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
    Penel N; Duhamel A; Adenis A; Devos P; Isambert N; Clisant S; Bonneterre J
    Invest New Drugs; 2012 Apr; 30(2):653-61. PubMed ID: 21049280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.